MX380367B - Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina. - Google Patents

Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.

Info

Publication number
MX380367B
MX380367B MX2017014743A MX2017014743A MX380367B MX 380367 B MX380367 B MX 380367B MX 2017014743 A MX2017014743 A MX 2017014743A MX 2017014743 A MX2017014743 A MX 2017014743A MX 380367 B MX380367 B MX 380367B
Authority
MX
Mexico
Prior art keywords
pancreatin
reducing
microbial content
manufacturing processes
inactivating viral
Prior art date
Application number
MX2017014743A
Other languages
English (en)
Other versions
MX2017014743A (es
Inventor
Anisha Akula
Carmen Fritz
Colin Crowley
Dana Spangenberg
Dustin Nielsen
Jon Restivo
Karla Anhalt
Kenneth S Manning
Mark Romich
Ryan Ruf
Yan Wang
Original Assignee
Scient Protein Laboratories Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scient Protein Laboratories Llc filed Critical Scient Protein Laboratories Llc
Publication of MX2017014743A publication Critical patent/MX2017014743A/es
Publication of MX380367B publication Critical patent/MX380367B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation
    • C12N2750/14363—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32261—Methods of inactivation or attenuation
    • C12N2770/32263—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método para la reducción inactivación del contenido viral y microbiano en la fabricación del ingrediente farmacéutico activo pancreatina. El método incluye tratar tejido derivado de animal con ácido peracético para reducir la actividad viral y la carga bacteriana antes del procesamiento. En particular, el método incluye tratar páncreas porcino con ácido peracético antes de extraer un ingrediente farmacéutico activo pancreatina del tejido glandular tratado.
MX2017014743A 2015-05-19 2016-05-19 Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina. MX380367B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163779P 2015-05-19 2015-05-19
US15/159,345 US10093916B2 (en) 2015-05-19 2016-05-19 Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin
PCT/US2016/033329 WO2016187455A1 (en) 2015-05-19 2016-05-19 Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin

Publications (2)

Publication Number Publication Date
MX2017014743A MX2017014743A (es) 2018-01-26
MX380367B true MX380367B (es) 2025-03-12

Family

ID=57320830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014743A MX380367B (es) 2015-05-19 2016-05-19 Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.

Country Status (7)

Country Link
US (2) US10093916B2 (es)
EP (1) EP3298139B1 (es)
CN (2) CN113750224B (es)
CY (1) CY1124679T1 (es)
MX (1) MX380367B (es)
PL (1) PL3298139T3 (es)
WO (1) WO2016187455A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298139B1 (en) * 2015-05-19 2021-09-15 Scientific Protein Laboratories LLC Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin
CN108795920B (zh) * 2018-06-22 2022-04-08 苏州良辰生物医药科技有限公司 一种胰酶的制备方法
CN109810968B (zh) * 2019-03-13 2021-03-02 淮安麦德森制药有限公司 胰酶的制备方法
CN112708611A (zh) * 2021-01-19 2021-04-27 四川菲德力制药有限公司 一种胰酶制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956483A (en) 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
US4986963A (en) 1989-01-24 1991-01-22 Corcoran Richard A Method of disinfecting contact lenses with peracetic acid
US20020192731A1 (en) * 2001-04-12 2002-12-19 H. Shih Jason C. Method and composition for sterilizing surgical instruments
US6749851B2 (en) 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
WO2004037168A2 (en) * 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
HUE031042T2 (en) * 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
KR101562682B1 (ko) * 2007-11-15 2015-10-22 애보트 래버러토리즈 게엠베하 판크레아틴 샘플내의 바이러스 로드의 분리 및 정량을 위한 신규방법
US20090130063A1 (en) 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2165717A1 (de) * 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
EP2295086B1 (de) 2008-11-03 2012-01-18 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung von Pankreatin
IN2012DN01577A (es) * 2009-07-21 2015-06-05 Transgene Sa
US9511125B2 (en) * 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2499240A1 (en) 2009-11-12 2012-09-19 Vbi Technologies, LLC Subpopulations of spore-like cells and uses thereof
CN102884181A (zh) 2010-03-19 2013-01-16 加拿大阿普塔利斯制药公司 用于药用胰腺酶制剂中的病毒灭活的β-丙内酯
EP3298139B1 (en) * 2015-05-19 2021-09-15 Scientific Protein Laboratories LLC Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin

Also Published As

Publication number Publication date
US11952603B2 (en) 2024-04-09
WO2016187455A1 (en) 2016-11-24
CN113750224A (zh) 2021-12-07
US20180362958A1 (en) 2018-12-20
PL3298139T3 (pl) 2022-01-31
EP3298139B1 (en) 2021-09-15
CN107849552B (zh) 2021-11-02
EP3298139A4 (en) 2019-02-06
CN113750224B (zh) 2024-04-30
CY1124679T1 (el) 2022-07-22
EP3298139A1 (en) 2018-03-28
US20170037392A1 (en) 2017-02-09
BR112017024920A2 (pt) 2018-07-31
CN107849552A (zh) 2018-03-27
MX2017014743A (es) 2018-01-26
US10093916B2 (en) 2018-10-09

Similar Documents

Publication Publication Date Title
CY1124679T1 (el) Μεθοδος μειωσης η απενεργοποιησης του ιικου και μικροβιακου περιεχομενου στις μεθοδους παρασκευης παγκρεατινης
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA202191067A1 (ru) Композиции и способы для лечения дефицита альфа-1-антитрипсина
BR112015013123A2 (pt) inibidores de beta-lactamase
MX384240B (es) Bacterias probioticas recombinantes.
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
EA201890728A2 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
EP3530124A4 (en) DIET CONTAINING A SUBTILUS BACILIUS STRAIN, BACILIUS PUMILUS STRAIN AND BACILIUS LICHENFORMIS STRAIN AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING ACUTE HEPATOPANCREATIC NECROSIS DISEASE OR BLANCHANCHESIS SYNDROME
UY36332A (es) Composiciones de bacillus pumilus rt1279 y metodos de uso para benefficiar el crecimiento de las plantas
PH12017501300A1 (en) Novel iodophor composition and methods of use
ZA202006612B (en) Antibacterial compounds
EA201791051A1 (ru) Способ лечения, профилактики или снижения риска возникновения кожной инфекции
GB201202561D0 (en) Treatment of skin disorders
MX386601B (es) Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
AR125341A2 (es) Conservante de heno y métodos de conservación del heno
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
EA201991530A1 (ru) Композиции и способы лечения биопленок
GB2571493A (en) Methods and products for reducing resistance to anti-parasitic agents
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood
EA202192668A1 (ru) Способ и композиция для терапевтического лечения непереносимости глютена
EA201992210A1 (ru) Предотвращение и/или лечение воспалительного заболевания кожи
PH12015502092A1 (en) Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
BR102018006534A8 (pt) Métodos para melhorar a atividade dos retinoides